{"id":"NCT01313507","sponsor":"Octapharma","briefTitle":"High Infusion Rate Study of Immunoglobulin Intravenous (Human) 10% (NewGam)","officialTitle":"Clinical Study to Evaluate the Safety and Tolerability of Immunoglobulin Intravenous (Human) 10% (NewGam) Administered at High Infusion Rates to Patients With Primary Immunodeficiency Diseases (Extension of Study NGAM-01)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2011-05","primaryCompletion":"2012-09","completion":"2012-09","firstPosted":"2011-03-11","resultsPosted":"2017-03-29","lastUpdate":"2017-03-29"},"enrollment":21,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Primary Immunodeficiency Disease"],"interventions":[{"type":"BIOLOGICAL","name":"NewGam","otherNames":[]}],"arms":[{"label":"NewGam","type":"EXPERIMENTAL"}],"summary":"This was a prospective, open-label, non-controlled, non-randomized multicenter Phase III study of 2 multiple-dose intravenous NewGam regimens (every 3 weeks or every 4 weeks, continuing the patient's infusion interval in the main study NCT01012323 \\[NGAM-01\\]) for 3 months. The primary objective of the study was to assess the safety and tolerability of high infusion rates of NewGam.","primaryOutcome":{"measure":"Percentage of Participants Who Experienced at Least 1 Adverse Event Causally Related to the Administration of the Study Drug","timeFrame":"Baseline (follow-up visit of study NGAM-01) to the end of the study (follow-up visit of study NGAM-05) (up to 4 months)","effectByArm":[{"arm":"NewGam","deltaMin":19,"sd":null}],"pValues":[]},"eligibility":{"minAge":"2 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":3},"locations":{"siteCount":6,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":21},"commonTop":["Sinusitis","Nausea","Vomiting","Abdominal pain","Diarrhoea"]}}